Anticoagulants — Heparin, Warfarin, DOACs

Intrinsic and Extrinsic Coagulation Cascade Mechanisms

• Unfractionated Heparin Mechanism: UFH is a heterogeneous, high-molecular-weight polysaccharide (average 15,000 Da) that binds antithrombin III (AT III), a serine protease inhibitor. Heparin-AT III complex undergoes conformational change, exponentially increasing AT III's catalytic activity against Factor IIa (thrombin), Factor Xa, and other activated factors (IXa, Xa, XIa, XIIa). UFH specifically catalyzes Factor IIa and Factor Xa neutralization through irreversible complex formation. Additionally, UFH directly neutralizes Factor IIa at high concentrations and enhances AT III's interaction with thrombin-fibrin complexes. Critically, UFH has a nonlinear pharmacokinetic profile due to binding to endothelial cells, macrophages, acute phase reactants, and platelet proteins, resulting in unpredictable absorption and clearance. This variable binding explains the necessity for weight-based dosing and activated partial thromboplastin time (aPTT) monitoring. The onset of action is immediate (seconds to minutes) following intravenous administration, making UFH ideal for acute thrombotic emergencies. Half-life ranges from 30 to 90 minutes at therapeutic doses, depending on plasma concentration.

• Low-Molecular-Weight Heparin Mechanism: LMWH consists of fragments (average 5,000-10,000 Da) produced by chemical or enzymatic degradation of UFH. These smaller molecules retain anti-Factor Xa activity through AT III-mediated mechanisms but have relatively reduced anti-Factor IIa activity, resulting in a Factor Xa:Factor IIa activity ratio of approximately 2:1 to 4:1 (compared to UFH's 1:1 ratio). This selective anti-Xa predominance provides several pharmacokinetic advantages: more predictable bioavailability (90-95%), more linear pharmacokinetics due to reduced nonspecific binding, longer half-life (3-6 hours allowing subcutaneous dosing once or twice daily), and less frequent monitoring requirements. Different LMWH preparations (enoxaparin, dalteparin, tinzaparin) have variable anti-Xa:anti-IIa ratios and are not considered interchangeable on a unit-for-unit basis. Anti-Xa activity is measured in milliunits per mL and can be monitored in specific populations (renal impairment, extremes of weight, pregnancy) though routine monitoring is unnecessary in most patients. LMWH has superior bioavailability at subcutaneous injection sites compared to UFH, facilitating outpatient administration and enabling bridge therapy with warfarin or prolonged LMWH monotherapy.

• Vitamin K Antagonist (Warfarin) Mechanism: Warfarin inhibits vitamin K epoxide reductase, blocking recycling of oxidized vitamin K to its reduced form. This disrupts the carboxylation of vitamin K-dependent clotting factors (Factors II, VII, IX, and X), which requires reduced vitamin K as a cofactor. Undercarboxylated factors are biologically inactive and cannot generate thrombin. Warfarin additionally inhibits carboxylation of natural anticoagulants protein C and protein S, which are also vitamin K-dependent. Protein C and S have shorter half-lives (8 hours and 42 hours respectively) compared to Factor II (72 hours), Factor IX (24 hours), Factor X (40 hours), and Factor VII (4-6 hours). During initial warfarin therapy, transient hypercoagulability occurs as protein C depletes rapidly before factors II, IX, and X decrease substantially. This explains the requirement for heparin bridge therapy during initial warfarin initiation. Warfarin's anticoagulant effect develops slowly over 5-7 days as preexisting vitamin K-dependent factors are consumed. International normalized ratio (INR) reflects the prothrombin time prolongation and correlates with warfarin's anticoagulant effect, with steady-state INR often achieved by day 5-7 but continuing to shift for 1-2 weeks due to Factor II's long half-life. Numerous drug interactions and dietary vitamin K variations necessitate regular INR monitoring to maintain therapeutic range.

• Direct Oral Anticoagulants Mechanism: DOACs comprise two mechanistically distinct classes: Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) and direct thrombin inhibitors (Factor IIa inhibitors) (dabigatran). Factor Xa inhibitors bind directly to the active site of Factor Xa, blocking its catalytic activity and preventing Factor Va-Factor Xa prothrombinase complex formation and subsequent thrombin generation. Dabigatran binds directly to thrombin's catalytic site with high specificity, preventing fibrinogen cleavage and thrombin-mediated amplification. Both classes achieve rapid anticoagulant onset (2-3 hours), achieve peak plasma concentration within 1-3 hours of oral dosing, have predictable pharmacokinetics enabling fixed-dose regimens without monitoring, and reach steady state within 3-5 days. Renal elimination varies significantly: dabigatran undergoes 80% renal clearance (highest renal dependence), edoxaban 50%, apixaban 27%, and rivaroxaban 66%. This renal dependence necessitates dose adjustments in severe renal impairment (creatinine clearance <30 mL/min for most DOACs). DOACs do not require monitoring of routine coagulation parameters because of their predictable pharmacokinetics; however, anti-Xa levels can be measured clinically in specific scenarios (renal failure, drug interactions, adherence assessment, reversal efficacy confirmation).

• Endogenous Anticoagulant Mechanisms—Protein C and Protein S: These are naturally occurring vitamin K-dependent proteins that limit thrombin generation. Protein C, activated by thrombin in the presence of protein S as cofactor, inactivates Factors Va and VIIIa, preventing further thrombin production. Protein S acts as a nonenzymatic cofactor enhancing protein C activity approximately 1000-fold. Both anticoagulants are depleted early in warfarin therapy before procoagulant factors II, IX, and X, explaining transient hypercoagulability. Deficiencies in protein C or S cause familial thrombophilia and warfarin skin necrosis (typically occurring on day 3-5 of therapy, particularly in large-breasted women and with high-dose warfarin initiation). Prevention involves adequate heparin bridge to maintain thrombin generation during early warfarin loading or using lower warfarin initiation doses (5 mg rather than 10 mg).

Indications for Anticoagulation — Venous Thromboembolism Prevention and Treatment

• Atrial Fibrillation with Stroke Risk: Atrial fibrillation (AF) represents the most common indication for anticoagulation in developed nations, affecting 2-3% of adults over 65 years with increasing prevalence in the elderly. AF predisposes to thromboembolism through reduced atrial contractility, atrial blood stasis, and endocardial remodeling. CHA₂DS₂-VASc score stratifies stroke risk: ≥2 points in males (≥3 in females) warrants anticoagulation, with 1-year stroke risk approximately 1% per point above threshold. Without anticoagulation, AF carries 4-6% annual ischemic stroke risk rising to >10% in high-risk patients. Particularly high-risk features include prior stroke/TIA (doubles risk), age >75 years, female sex, diabetes mellitus, hypertension, left ventricular dysfunction, and left atrial enlargement.

• Acute Coronary Syndrome: Recent acute myocardial infarction (AMI), particularly with anterior wall involvement causing left ventricular dysfunction or apical thrombus formation, requires anticoagulation to prevent systemic thromboembolism (risk 1-10% without anticoagulation). Anticoagulation is combined with antiplatelet agents (dual antiplatelet therapy with aspirin plus P2Y₁₂ inhibitor) in acute coronary syndromes, creating complex bleeding-thrombosis risk balance.

• Mechanical Heart Valves and Rheumatic Mitral Stenosis: Mechanical prosthetic heart valves carry the highest thromboembolism risk (1-2% per year even with anticoagulation), necessitating warfarin specifically (DOACs are contraindicated and inferior in this setting). Rheumatic mitral stenosis combined with AF carries substantial thromboembolism risk due to left atrial enlargement, blood stasis, and endothelial injury. Bioprosthetic valves require anticoagulation for only 3 months post-operatively in normal sinus rhythm unless other indications exist.

• Thrombophilia and Inherited Coagulation Disorders: Inherited thrombophilias (Factor V Leiden present in 5-8% of Caucasian population with 2-8 fold VTE risk; prothrombin G20210A mutation in 2% with 2-3 fold risk; antithrombin, protein C, or protein S deficiency with 5-10 fold risk) warrant long-term anticoagulation following VTE occurrence. Homozygous Factor V Leiden or compound heterozygosity markedly escalates thromboembolism risk. Antiphospholipid antibody syndrome, an acquired thrombophilia characterized by lupus anticoagulant, anticardiolipin antibodies, or β₂-glycoprotein I antibodies, requires indefinite anticoagulation after first VTE with particularly high recurrence risk.

• Malignancy-Associated Thrombosis: Cancer increases VTE risk 20-fold through tissue factor expression, platelet activation, fibrin deposition, and circulating microparticles. Malignancy-associated thrombosis accounts for approximately 20% of new VTE diagnoses. Certain cancers (pancreatic, lung, gastric, brain) carry particularly high VTE risk (>10-20% annually). Cancer patients typically require extended anticoagulation duration (minimum 6 months even for provoked VTE) and LMWH may be preferred over warfarin based on some trial evidence suggesting superior efficacy.

Clinical Manifestations of Thromboembolism—Indications for Anticoagulant Therapy

• Deep Vein Thrombosis Manifestations: DVT presents with unilateral lower extremity swelling, pain, erythema, and warmth resulting from venous obstruction, inflammation, and impaired venous return. Classic presentation includes calf or thigh swelling (measured circumference difference >3 cm compared to contralateral leg), pain on dorsiflexion (Homan's sign—though nonspecific and insensitive), and palpable cord-like vein. Proximal DVT (popliteal, femoral, or iliac veins) causes more significant swelling and carries higher PE risk (20-30% if untreated). Distal DVT (calf veins) causes minimal symptoms but carries lower PE risk (2-5% if untreated). May's-Thurner syndrome describes left iliac vein compression by right iliac artery causing left lower extremity DVT in younger patients without typical risk factors. Post-thrombotic syndrome develops in 20-50% of DVT patients despite anticoagulation, manifesting as chronic leg swelling, pain, skin pigmentation changes, and venous ulceration resulting from persistent venous hypertension and valvular incompetence.

• Pulmonary Embolism Manifestations: PE presents with sudden-onset dyspnea, pleuritic chest pain, hemoptysis (20% of cases), tachycardia, and tachypnea reflecting acute right ventricular strain and hypoxemia. Massive PE (involving >2 pulmonary arteries or causing hemodynamic compromise) precipitates acute cor pulmonale with hypotension, syncope, elevated jugular venous pressure, right ventricular heave, and accentuated pulmonary component of S₂. Physiology involves increased pulmonary vascular resistance, right ventricular afterload, and decreased cardiac output. Submassive PE causes elevated troponin and N-terminal BNP reflecting right ventricular dysfunction without hemodynamic collapse. Wells score and PERC (Pulmonary Embolism Rule-out Criteria) stratify PE probability pretest, with D-dimer testing reserved for intermediate/high probability cases to avoid unnecessary imaging.

• Ischemic Stroke from Atrial Fibrillation: AF-related stroke results from left atrial appendage thrombi embolizing to cerebral circulation, causing acute neurological deficit consistent with arterial territory (anterior circulation causing contralateral hemiparesis, aphasia, hemianopia; posterior circulation causing vertigo, diplopia, ataxia, crossed syndromes). AF-associated strokes are more severe and disabling compared to other stroke etiologies, with 30-day mortality reaching 5-10% and permanent disability in >50% of survivors without prevention. Asympto

Heparins (UFH and LMWH)

• Bleeding: the dominant dose-dependent toxicity; monitor aPTT (or anti-Xa) for UFH, CBC for hemoglobin/platelet drift. Protamine sulfate fully neutralizes UFH by ionic binding of the polyanionic heparin chain but only partially reverses LMWH (short pentasaccharide fragments escape binding); protamine can cause hypotension and anaphylactoid reactions, notably after prior NPH insulin exposure.
• Heparin-induced thrombocytopenia (HIT, type II): IgG antibodies against heparin–platelet factor 4 complexes cross-link platelet FcγRIIa, causing platelet activation, thrombin burst, and paradoxical arterial/venous thrombosis with a >50% platelet fall typically on days 5–10. ASH's 2018 HIT guideline directs use of the 4T score, immediate cessation of all heparin, and a non-heparin anticoagulant (argatroban, bivalirudin, or fondaparinux); avoid prophylactic platelet transfusion.
• Other UFH effects: hyperkalemia from aldosterone synthesis suppression, osteoporosis and transaminitis with prolonged use. Heparin fails when antithrombin is deficient (heparin resistance).

Warfarin

• Bleeding with narrow therapeutic index: requires serial INR; CYP2C9 and VKORC1 variants, dietary vitamin K, and countless drug interactions (amiodarone, TMP-SMX, azoles, rifampin) shift the INR.
• Warfarin-induced skin necrosis: early protein C depletion produces transient hypercoagulability with dermal microvascular thrombosis, classically days 3–5 in protein C/S deficiency — prevented by heparin overlap and avoiding large loading doses. Purple toe syndrome reflects cholesterol microembolization.
• Teratogenicity: crosses the placenta causing fetal warfarin syndrome (nasal hypoplasia, stippled epiphyses) and fetal hemorrhage; ACOG favors LMWH in pregnancy.
• Reversal: hold drug ± oral vitamin K for elevated INR without bleeding; for major/life-threatening bleeding the ACC expert consensus pathway on oral anticoagulant bleeding and CHEST guidance recommend IV vitamin K plus four-factor prothrombin complex concentrate (FFP only if PCC unavailable).

DOACs

• Bleeding, with more gastrointestinal bleeding than warfarin for dabigatran and rivaroxaban but less intracranial hemorrhage; dabigatran also causes dyspepsia.
• Accumulation in renal impairment (dabigatran most renally cleared) and interactions with P-glycoprotein/CYP3A4 modulators.
• Reversal: idarucizumab for dabigatran; andexanet alfa for apixaban/rivaroxaban; vitamin K is useless.
• Contraindications: mechanical valves and moderate-to-severe rheumatic mitral stenosis (ACC/AHA valvular guideline — warfarin only), and triple-positive antiphospholipid syndrome.
• Spinal/epidural hematoma with neuraxial procedures — observe ASRA interval recommendations.

• Monitoring pairings: UFH → aPTT (or anti-Xa heparin assay); warfarin → PT/INR; LMWH, fondaparinux, and DOACs → no routine monitoring, with anti-Xa levels reserved for pregnancy, obesity, renal failure, or adherence questions.
• Platelet count falling on day 5–10 of heparin with new thrombosis is HIT until proven otherwise. Single best next step: stop all heparin (including flushes and coated catheters) and start a non-heparin agent such as argatroban — not simply "observe" and not warfarin alone, which precipitates venous limb gangrene through protein C depletion.
• Skin necrosis days 3–5 after warfarin loading points to underlying protein C or S deficiency; the tested principle is that the shortest-half-life factors (VII, t½ ~6 h) and protein C fall first, so early INR rise does not mean the patient is antithrombotic — hence heparin overlap for at least 5 days and until INR is therapeutic.
• Heparin given but aPTT won't budge = antithrombin deficiency (heparin resistance), since heparin works only as an antithrombin catalyst.
• Reversal agent matching is a favorite one-liner: protamine → UFH (partial for LMWH, useless for fondaparinux); vitamin K + 4-factor PCC → warfarin; idarucizumab → dabigatran; andexanet alfa → apixaban/rivaroxaban.
• The one association examiners test: mechanical prosthetic valves and moderate-to-severe rheumatic mitral stenosis require warfarin, per the ACC/AHA valvular heart disease guideline — a DOAC is always the wrong answer there. Conversely, for nonvalvular atrial fibrillation, ACC/AHA/HRS atrial fibrillation guidance prefers DOACs over warfarin in eligible patients.
• Pregnancy: LMWH is the anticoagulant of choice (does not cross the placenta); warfarin is teratogenic and DOACs lack safety data. Do not extrapolate "short half-life makes it safer" logic to any agent in pregnancy.
• Common distractor: an isolated prolonged aPTT that fails to correct on mixing study in a patient with thrombosis and fetal loss is lupus anticoagulant — a prothrombotic state requiring warfarin, not a bleeding disorder.